Current Infectious Disease Reports

, Volume 12, Issue 5, pp 361–367

Adjunct Therapy for Sepsis: How Early?



Sepsis is a leading cause of death worldwide. The management of patients is primarily based on curing the infectious process with anti-infective drugs and/or surgical drainage. Simultaneously, treatment includes optimization of oxygen use by tissues via appropriate oxygen therapy and respiratory and hemodynamic management. At best, initiating appropriate anti-infective and symptomatic treatments should lead to patient improvement within a few hours. Activated protein C and hydrocortisone are the only two available adjunct therapies for sepsis. These treatments should optimally be started within 24 hours of the onset of shock. They should be initiated in those patients who did not adequately respond after 6 hours of optimal anti-infective and symptomatic treatments.


Infection Inflammation Apoptosis Coagulation Shock Organ dysfunction Hydrocortisone Activated protein C 


Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. 1.
    Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303–1310.CrossRefPubMedGoogle Scholar
  2. 2.
    Annane D, Sébille V, Charpentier C, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862–871.CrossRefPubMedGoogle Scholar
  3. 3.
    Bernard GR, Vincent JL, Laterre PF, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699–709.CrossRefPubMedGoogle Scholar
  4. 4.
    • Riedemann T, Patchev AV, Cho K, Almeida OF: Corticosteroids: way upstream. Mol Brain 2010, 3:2. This article provides a comprehensive update of knowledge about corticosteroids’ mechanisms of action.CrossRefPubMedGoogle Scholar
  5. 5.
    Annane D: Glucocorticoids in the treatment of severe sepsis and septic shock. Curr Opin Crit Care 2005, 11:449–453.CrossRefPubMedGoogle Scholar
  6. 6.
    Muhlfelder TW, Niemetz J, Kang S: Glucocorticoids inhibit the generation of leukocyte procoagulant (tissue factor) activity. Blood 1982, 60:1169–1172.PubMedGoogle Scholar
  7. 7.
    van Giezen JJ, Jansen JW: Inhibition of fibrinolytic activity in-vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation. Thromb Haemost 1992, 68:69–73.PubMedGoogle Scholar
  8. 8.
    Jorgensen KA, Sorensen P, Freund L: Effect of glucocorticosteroids on some coagulation tests. Acta Haematol 1982, 68:39–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Patrassi GM, Sartori MT, Livi U, et al.: Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation. Transplantation 1997, 64:1610–1614.CrossRefPubMedGoogle Scholar
  10. 10.
    `Schmidt S, Rainer J, Ploner C, et al.: Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004, 11(Suppl 1):S45–S55.CrossRefPubMedGoogle Scholar
  11. 11.
    Cronin L, Cook DJ, Carlet J, et al.: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23:1430–1439.CrossRefPubMedGoogle Scholar
  12. 12.
    Annane D, Sébille V, Troché G, et al.: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000, 283:1038–1045.CrossRefPubMedGoogle Scholar
  13. 13.
    • Marik PE, Pastores SM, Annane D, et al.: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008, 36:1937–1949. This article provides a comprehensive approach to the rationale and clinical evidence for the use of corticosteroids in critical illness.CrossRefPubMedGoogle Scholar
  14. 14.
    •• Annane D, Bellissant E, Bollaert PE, et al.: Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009, 301:2362–2375. This systematic review clearly establishes the current evidence favoring the use of corticosteroids in septic shock. In addition, it provides useful information on the practical modalities for using corticosteroids in septic shock.CrossRefPubMedGoogle Scholar
  15. 15.
    •• COIITSS Study Investigators, Annane D, Cariou A, Maxime V, et al.: Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010, 303:341–348. This is the first multicenter, randomized, controlled trial investigating the benefit-to-risk ratio of normalizing blood glucose levels in corticosteroid-treated patients. The study demonstrated that tight glucose control was not superior to moderate glucose control.CrossRefPubMedGoogle Scholar
  16. 16.
    •• Sprung C, Annane D, Keh D, et al.: The CORTICUS randomized, double-blind, placebo-controlled study of hydrocortisone therapy in patients with septic shock. N Engl J Med 2008, 358:111–124. This article challenges the benefit of corticosteroids in septic shock. Although hydrocortisone therapy hastens shock reversal and organ dysfunction resolution, no evidence was shown for survival benefit and there was an apparent increase in superinfections.CrossRefPubMedGoogle Scholar
  17. 17.
    • Dellinger RP, Levy MM, Carlet JM, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296–327. This article provides the current guidelines for the management of sepsis.CrossRefPubMedGoogle Scholar
  18. 18.
    Hinshaw LB, Archer LT, Beller-Todd BK, et al.: Survival of primates in lethal septic shock following delayed treatment with steroid. Circ Shock 1981, 8:291–300.PubMedGoogle Scholar
  19. 19.
    Cicarelli DD, Vieira JE, Bensenor FE: Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial. Sao Paulo Med J 2007, 125:237–241.CrossRefPubMedGoogle Scholar
  20. 20.
    Yildiz O, Doganay M, Aygen B, et al.: Physiologic-dose steroid therapy in sepsis. Crit Care 2002, 6:251–259.CrossRefPubMedGoogle Scholar
  21. 21.
    Oppert M, Schindler R, Husung C, et al.: Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005, 33:2457–2464.CrossRefPubMedGoogle Scholar
  22. 22.
    Tandan SM, Guleria R, Gupta N: Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India [abstract]. Proceedings of the American Thoracic Society Meeting. New York: American Thoracic Society; 2005:A24.Google Scholar
  23. 23.
    Bollaert PE, Charpentier C, Levy B, et al.: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26:645–650.CrossRefPubMedGoogle Scholar
  24. 24.
    Briegel J, Forst H, Haller M, et al.: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999, 27:723–732.CrossRefPubMedGoogle Scholar
  25. 25.
    Chawla K, Kupfer Y, Tessler S: Hydrocortisone reverses refractory septic shock. Crit Care Med 1999, 27:A33.CrossRefGoogle Scholar
  26. 26.
    •• Meduri GU, Golden E, Freire AX, et al.: Methylprednisolone infusion in early ARDS: result of a randomised controlled trial. Chest 2007, 131:954–963. This article describes the first multicenter trial of moderate doses of corticosteroids in early ARDS patients. There was strong evidence for morbidity benefits.CrossRefPubMedGoogle Scholar
  27. 27.
    Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005, 365:63–78.Google Scholar
  28. 28.
    Toussaint S, Gerlach H: Activated protein C for sepsis. N Engl J Med 2009, 361:2646–2652.CrossRefPubMedGoogle Scholar
  29. 29.
    Levi M, van der Poll T: Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007, 11(Suppl 5):S3.CrossRefPubMedGoogle Scholar
  30. 30.
    Yuksel M, Okajima K, Uchiba M, et al.: Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002, 88:267–273.PubMedGoogle Scholar
  31. 31.
    Cheng T, Liu D, Griffin JH, et al.: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003, 9:338–342.CrossRefPubMedGoogle Scholar
  32. 32.
    Dömötör E, Benzakour O, Griffin JH, et al.: Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 2003, 101:4797–4801.CrossRefPubMedGoogle Scholar
  33. 33.
    Mosnier LO, Griffin JH: Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003, 373:65–70.CrossRefPubMedGoogle Scholar
  34. 34.
    Montori VM, Devereaux PJ, Adhikari NK, et al.: Randomized trials stopped early for benefit: a systematic review. JAMA 2005, 294:2203–2209.CrossRefPubMedGoogle Scholar
  35. 35.
    Ely EW, Laterre P-F, Angus DC, et al.: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003, 31:12–19.CrossRefPubMedGoogle Scholar
  36. 36.
    Abraham E, Laterre PF, Garg R, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332–1341.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Nadel S, Goldstein B, Williams MD, et al.: Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836–843. This was the largest trial of activated protein C in children. There was no apparent benefit and an increased risk of serious bleeding.CrossRefPubMedGoogle Scholar
  38. 38.
    • Marti-Carvajal A, Salanti G, Cardona A: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev, 2008:CD004388. This is an important systematic review challenging the benefit-to-risk ratio of activated protein C.Google Scholar
  39. 39.
    • Levi M, Levy M, Williams MD, et al.: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007, 176:483–490. This trial demonstrated no significant interaction between activated protein C and prophylactic heparin.CrossRefPubMedGoogle Scholar
  40. 40.
    Vincent JL, Bernard GR, Beale R, et al.: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005, 33:2266–2277.CrossRefPubMedGoogle Scholar
  41. 41.
    Vincent J-L, O’Brien J Jr, Wheeler A, et al.: Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 2006, 10:R74.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.General Intensive Care Unit, Raymond Poincaré hospital (AP-HP)University of Versailles SQYGarchesFrance

Personalised recommendations